Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo

A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news